BioLineRx Ltd. (BLRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

BioLineRx Ltd. (BLRX) closed at USD 2.08 on 2026-10-14, a change of -43.5 % over the past year, with a market capitalization of USD 10.21M.

BioLineRx Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BioLineRx Ltd. key figures

Previous close

USD 2.08 (2026-10-14)

1-year change

-43.5 %

Market cap

USD 10.21M

Enterprise value

USD 6.67M

P/E ratio (trailing)

n/a

P/E ratio (forward)

-0.81

EPS (trailing)

0.00

EPS (forward)

-2.52

PEG ratio

n/a

Price to book

0.68

Revenue growth

-3.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.30

Employees

20

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BioLineRx Ltd.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BioLineRx Ltd. and compare it with other stocks.